Back to Company Profile
Alpha

Alpha Profiles · Company Profile

Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments.

https://registry.alpha.ac/companies/aardvark-therapeutics-inc

Aardvark Therapeutics, Inc. logo
Entity
Public listing published
Primary listing
NASDAQ: AARD
Verification
Partially verified
Last reviewed
2026-09-25T04:47:14.843629+00:00

Overview

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

1 public record
NS
Nelson Sun

Chief Financial Officer and Chief Operating Officer

State
unconfirmed
Effective
From Jul 10, 2026
Confidence
88%
Evidence
DEF 14AJul 10, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 25, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

5 public records
JC
Jeffrey Chi

Director

Independence not stated
State
confirmed
Effective
From Jan 1, 2019
Confidence
88%
Evidence
DEF 14AJul 10, 2026
RD
Roy D. Baynes

Director

Independence not stated
State
confirmed
Effective
From Jan 1, 2024
Confidence
88%
Evidence
DEF 14AJul 10, 2026
SE
Susan E. Graf

Director

Independence not stated
State
confirmed
Effective
From Jan 1, 2024
Confidence
88%
Evidence
DEF 14AJul 10, 2026
TL
Tien-Li Lee

Director

Independence not stated
State
confirmed
Effective
From Jan 1, 2017
Confidence
88%
Evidence
DEF 14AJul 10, 2026
VT
Victor Tong, Jr

Director

Independence not stated
State
confirmed
Effective
From Jan 1, 2024
Confidence
88%
Evidence
DEF 14AJul 10, 2026

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-09-25T04:47:14.843629+00:00

Generated 2026-09-25T20:47:22.012Z

Data as of 2026-09-25T04:47:14.843629+00:00

https://registry.alpha.ac/companies/aardvark-therapeutics-inc